CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2026)

CRISPR Therapeutics AG has disclosed EBT Margin across 11 years of filings, most recently posting 885.91% for Q2 2026.

• In Q2 2026, EBT Margin rose 2234918.0% year-over-year to 885.91%; the TTM figure through Jun 2026 stood at 3588.96% (down 226162.0% YoY), while the FY2025 annual figure was 17392.93%, down 1631051.0% from the prior year.
• EBT Margin came in at 885.91% for Q2 2026 at CRISPR Therapeutics AG, up from 8373.94% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 29.43% in Q4 2023 to a low of 2022866.67% in Q4 2022.
• Average EBT Margin over 5 years is 146004.1%, with a median of 15593.87% recorded in 2025.
• Year-over-year, EBT Margin sank 202175417 bps in 2022 and surged 202289610 bps in 2023.
• Over 5 years, EBT Margin stood at 2022866.67% in 2022, then jumped by 100 bps to 29.43% in 2023, then slumped by 841 bps to 218.1% in 2024, then sank by 8525 bps to 18810.88% in 2025, then soared by 95 bps to 885.91% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 885.91% in Q2 2026, 8373.94% in Q1 2026, and 18810.88% in Q4 2025.